回盛生物: 董事会决议公告

Group 1 - The board of directors of Wuhan Huirong Biological Technology Co., Ltd. held its 23rd meeting on August 5, 2025, with all five directors present, and the meeting complied with relevant laws and regulations [1] - The board unanimously approved the 2025 semi-annual report, confirming that it accurately reflects the company's operational status without any false statements or omissions [2][3] - The board approved the special report on the use of raised funds, ensuring compliance with relevant regulations and confirming no violations in the management and disclosure of raised funds [2][3] Group 2 - The board proposed a profit distribution plan for the first half of 2025, recommending a cash dividend of 20,157,895.70 yuan (before tax) based on a total share capital of 202,332,557 shares as of June 30, 2025 [2][3] - The profit distribution plan does not require shareholder meeting approval as it was authorized in the 2024 annual shareholder meeting [3] - The board approved the appointment of Han Jie as the rotating general manager, with the term lasting until the end of the current board's term [4] Group 3 - The board approved an investment of 170 million yuan in a project to upgrade veterinary raw material production equipment, aimed at enhancing product quality and increasing production capacity [5] - The company plans to change its registered capital from 179,194,432 yuan to 202,332,557 yuan due to the conversion of convertible bonds into shares, and to relocate its registered address [6] - The board agreed to convene the second extraordinary general meeting of shareholders on August 22, 2025 [6]